ArticleBMC medical imaging2025
Impact of abdominal adipose tissue segmentation on radiomics-based prognostic evaluation using CT enterography in Crohn's disease.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTo evaluate the impact of different abdominal adipose tissue segmentation strategies on radiomics-based models for predicting 3-year disease progression in patients with Crohn's disease (CD).
methodsIn this retrospective dual-center study, patients with CD who underwent baseline CT enterography (CTE) were included. Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were segmented using three approaches: (1) whole-abdomen segmentation (T-VAT/SAT); (2) single-slice segmentation of adipose tissue surrounding the most severely affected bowel segment (LL-VAT/SAT); and (3) single-slice segmentation at individual vertebral levels from L3 to S2 (V-VAT/SAT). Radiomic features were extracted after preprocessing, and redundant features were removed. Feature selection was performed using the least absolute shrinkage and selection operator (LASSO), followed by construction of logistic regression models. A combined model incorporating radiomics and clinical features was also constructed. Model performance was evaluated using receiver operating characteristic (ROC), area under the precision-recall curve (AUPRC), and decision curve analysis (DCA).
resultsIn the external test set, the T-VAT model achieved an AUC of 0.877 (95% CI: 0.718-0.937) and an AUPRC of 0.657 (95% CI: 0.368-1.000), performing better than other VAT- and SAT-based models. The combined model, which incorporated clinical features with the T-VAT model, showed an AUC of 0.873 (95% CI: 0.711-1.000) and the highest AUPRC of 0.666 (95% CI: 0.376-1.000). DCA further demonstrated that the combined model provided greater net clinical benefit compared with both the T-VAT and clinical models.
conclusionsRadiomics based on whole-abdominal VAT segmentation achieved the best prognostic performance for predicting disease progression in CD. Appropriate selection of adipose tissue segmentation strategy is critical for developing robust radiomics models for outcome prediction. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.